Peter Lawson
Stock Analyst at Barclays
(1.18)
# 3,353
Out of 4,814 analysts
99
Total ratings
33.33%
Success rate
-17.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $22 → $5 | $3.08 | +62.34% | 6 | Apr 14, 2025 | |
| BMEA Biomea Fusion | Maintains: Equal-Weight | $11 → $3 | $1.71 | +75.44% | 5 | Apr 2, 2025 | |
| TCRX TScan Therapeutics | Maintains: Overweight | $14 → $3 | $1.53 | +96.08% | 2 | Mar 7, 2025 | |
| GERN Geron | Maintains: Overweight | $9 → $4 | $1.36 | +195.20% | 1 | Feb 27, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $25 → $29 | $35.59 | -18.52% | 5 | Feb 13, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $48 → $32 | $8.75 | +265.71% | 7 | Feb 3, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $25 → $29 | $7.70 | +276.87% | 6 | Oct 25, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $54 → $60 | $36.58 | +64.02% | 3 | Sep 27, 2024 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $14 → $17 | $2.77 | +514.83% | 5 | Sep 10, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $32 → $33 | $11.94 | +176.50% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $29.47 | +123.96% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.38 | +479.71% | 8 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $105 | $84.22 | +24.67% | 10 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $10.57 | +193.28% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $8.84 | +92.31% | 3 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $1.38 | +845.45% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $63 | $37.05 | +70.04% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $10 | $1.26 | +696.81% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $2 → $1 | $0.25 | +307.33% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.80 | +526.02% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $210 → $120 | $5.35 | +2,142.99% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.59 | +295.26% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $0.74 | +371.38% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $72.00 | +406.94% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $27.38 | +68.01% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $28 | $10.58 | +164.65% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.62 | +4,706.92% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $1.34 | +3,270.79% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $37.77 | +19.14% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.72 | +9,680.63% | 1 | Jul 14, 2017 |
Iovance Biotherapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $22 → $5
Current: $3.08
Upside: +62.34%
Biomea Fusion
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.71
Upside: +75.44%
TScan Therapeutics
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.53
Upside: +96.08%
Geron
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.36
Upside: +195.20%
Exelixis
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $25 → $29
Current: $35.59
Upside: -18.52%
Arvinas
Feb 3, 2025
Maintains: Overweight
Price Target: $48 → $32
Current: $8.75
Upside: +265.71%
Arcus Biosciences
Oct 25, 2024
Maintains: Overweight
Price Target: $25 → $29
Current: $7.70
Upside: +276.87%
Revolution Medicines
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $36.58
Upside: +64.02%
Relay Therapeutics
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $2.77
Upside: +514.83%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $11.94
Upside: +176.50%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $29.47
Upside: +123.96%
Jul 31, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.38
Upside: +479.71%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $75 → $105
Current: $84.22
Upside: +24.67%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $10.57
Upside: +193.28%
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $8.84
Upside: +92.31%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $1.38
Upside: +845.45%
Feb 29, 2024
Maintains: Overweight
Price Target: $47 → $63
Current: $37.05
Upside: +70.04%
Feb 27, 2024
Maintains: Overweight
Price Target: $6 → $10
Current: $1.26
Upside: +696.81%
Aug 10, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $0.25
Upside: +307.33%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.80
Upside: +526.02%
Aug 5, 2022
Maintains: Overweight
Price Target: $210 → $120
Current: $5.35
Upside: +2,142.99%
Jul 28, 2022
Initiates: Overweight
Price Target: $30
Current: $7.59
Upside: +295.26%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $0.74
Upside: +371.38%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $72.00
Upside: +406.94%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $27.38
Upside: +68.01%
Mar 4, 2020
Initiates: Underweight
Price Target: $28
Current: $10.58
Upside: +164.65%
Mar 4, 2020
Initiates: Overweight
Price Target: $30
Current: $0.62
Upside: +4,706.92%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $1.34
Upside: +3,270.79%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $37.77
Upside: +19.14%
Jul 14, 2017
Initiates: Buy
Price Target: $70
Current: $0.72
Upside: +9,680.63%